Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 2/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30185446 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CSNK2A1CYP2A6ALDH1A3KDM4E | |
| SCHEMBL30185447 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CSNK2A1CYP2A6ALDH1A3KDM4E | |
| SCHEMBL13638172 | 0.87 | ALDH1A1 (0.53) | ALDH1A1ALDH1A3MEN1NPC1KMT2A | |
| SCHEMBL8176964 | 0.85 | ALDH1A1 (0.55) | ALDH1A1CSNK2A1CYP2A6ALDH1A3KDM4E | |
| SCHEMBL30679643 | 0.84 | ALDH1A1 (0.50) | ALDH1A1ALDH1A3MEN1NPC1KMT2A | |
| SCHEMBL35967 | 0.82 | ALDH1A1 (0.48) | ALDH1A1CYP2A6KDM4EMEN1NPC1 | |
| SCHEMBL4887408 | 0.81 | ALDH5A1 (0.52) | ALDH1A1ALDH1A3KDM4EVCAM1HSD17B10 | |
| SCHEMBL25613984 | 0.81 | ALDH1A1 (0.55) | ALDH1A1ALDH1A3MEN1KMT2AVCAM1 | |
| SCHEMBL8759091 | 0.81 | CSNK2A1 (0.49) | ALDH1A1CSNK2A1CYP2A6NPC1HSD17B10 | |
| SCHEMBL5490742 | 0.78 | ALDH1A1 (0.50) | ALDH1A1CYP2A6KDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1075480-A4 | PURIFICATION OF CARBOXALDEHYDE | LILLY CO ELI (US) | 2002-01-23 | — | — | EP | claimed |
| EP-1075480-A1 | PURIFICATION OF CARBOXALDEHYDE | ELI LILLY AND COMPANY (US) | 2001-02-14 | — | — | EP | claimed |
| WO-1999057123-A1 | PURIFICATION OF CARBOXALDEHYDE | ELI LILLY AND COMPANY (US) | 1999-11-11 | — | — | WO | claimed |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| EP-4584267-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| WO-2024052692-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| EP-4301752-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| CN-117295736-A | Benzo [ C ] [2,6] naphthyridine derivatives, compositions thereof and therapeutic uses thereof | 剑桥实业有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| EP-1501509-A4 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| CN-1960969-A | Histamine H3 receptor agents, methods of preparation and therapeutic uses thereof | LILLY CO ELI (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1501509-A2 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004024061-A2 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1075480-A4 | PURIFICATION OF CARBOXALDEHYDE | LILLY CO ELI (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1075480-A1 | PURIFICATION OF CARBOXALDEHYDE | ELI LILLY AND COMPANY (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999057123-A1 | PURIFICATION OF CARBOXALDEHYDE | ELI LILLY AND COMPANY (US) | 1999-11-11 | — | — | WO | disclosed |
| US-3966801-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3950427-A | ANTIINFLAMMATORY, ANTIPYRETIC | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | ALDH1A1 2913/4885CSNK2A1 3/4885CYP2A6 1259/4885 |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | ABCB11, CEL, NDC1 | ALDH1A1 681/4885CSNK2A1 517/4885CYP2A6 113/4885 |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | ALDH1A1 2913/4885CSNK2A1 3/4885CYP2A6 1259/4885 |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | ALDH1A1 3874/4885CSNK2A1 5/4885CYP2A6 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.